OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Wei Zhou, Peng Fang, Dongan Yu, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 8, pp. 913-925
Open Access | Times Cited: 13
Wei Zhou, Peng Fang, Dongan Yu, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 8, pp. 913-925
Open Access | Times Cited: 13
Showing 13 citing articles:
Therapeutic prospects of nectin-4 in cancer: applications and value
Kaiyue Li, Yujing Zhou, Maolin Zang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 13
Kaiyue Li, Yujing Zhou, Maolin Zang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 13
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer
Yue Wu, Min Zhu, Baihe Sun, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Yue Wu, Min Zhu, Baihe Sun, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence
Mohammad Javad Khosravanian, Yousef Mirzaei, Ali Hussein Mer, et al.
Life Sciences (2024) Vol. 352, pp. 122910-122910
Closed Access | Times Cited: 7
Mohammad Javad Khosravanian, Yousef Mirzaei, Ali Hussein Mer, et al.
Life Sciences (2024) Vol. 352, pp. 122910-122910
Closed Access | Times Cited: 7
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
Huixia Huang, Yuxin Zhou, Chengzhang Shang, et al.
Investigational New Drugs (2025)
Closed Access
Huixia Huang, Yuxin Zhou, Chengzhang Shang, et al.
Investigational New Drugs (2025)
Closed Access
RP-HPLC can be used to determine an Enfortumab vedotin monoclonal antibody drug conjugate for treating urothelial cancer in an efficient rapid and quantitative manner
Chandra Sekhara Rao Gurugubelli, Suman Pallapati, Srinivasa Rao Pinapati
Analytical Chemistry Letters (2025), pp. 1-13
Closed Access
Chandra Sekhara Rao Gurugubelli, Suman Pallapati, Srinivasa Rao Pinapati
Analytical Chemistry Letters (2025), pp. 1-13
Closed Access
A Peptide Derived from Nectin-4 Increases Cisplatin Cytotoxicity in Cell Lines and Cells from Ovarian Cancer Patients’ Ascites
Kristin L.M. Boylan, Christoph Walz, Alexandra Schefter, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 901-901
Open Access
Kristin L.M. Boylan, Christoph Walz, Alexandra Schefter, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 901-901
Open Access
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study
Jian Zhang, Ruifeng Liu, Shixuan Wang, et al.
Annals of Oncology (2025)
Closed Access
Jian Zhang, Ruifeng Liu, Shixuan Wang, et al.
Annals of Oncology (2025)
Closed Access
Progress in the study of antibody-drug conjugates for the treatment of cervical cancer
Cong-Cong Zhai, Yan Cui, Ling Guo, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Cong-Cong Zhai, Yan Cui, Ling Guo, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
Yangyang Gao, Yuwei Xia, Yixin Chen, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Yangyang Gao, Yuwei Xia, Yixin Chen, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Development and validation of bioanalytical assays for the quantification of 9MW2821, a nectin-4-targeting antibody–drug conjugate
Peng Fang, Meng You, Yuxia Cao, et al.
Journal of Pharmaceutical and Biomedical Analysis (2024) Vol. 248, pp. 116318-116318
Open Access | Times Cited: 2
Peng Fang, Meng You, Yuxia Cao, et al.
Journal of Pharmaceutical and Biomedical Analysis (2024) Vol. 248, pp. 116318-116318
Open Access | Times Cited: 2
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Caroline Taylor, Kamai M. Patterson, Devira Friedman, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3071-3071
Open Access | Times Cited: 1
Caroline Taylor, Kamai M. Patterson, Devira Friedman, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3071-3071
Open Access | Times Cited: 1
Harnessing Leptolyngbya for antiproliferative and antimicrobial metabolites through lens of modern techniques: A review
Rahul Negi, Manisha Nigam, Rahul Singh
Algal Research (2024) Vol. 83, pp. 103702-103702
Closed Access | Times Cited: 1
Rahul Negi, Manisha Nigam, Rahul Singh
Algal Research (2024) Vol. 83, pp. 103702-103702
Closed Access | Times Cited: 1
Preclinical Evaluation of an Al18F-Radiolabeled Bicyclic Peptide Targeting Nectin-4
Xiaojiang Duan, Zhuochen Zhang, Hongchuang Xu, et al.
Molecular Pharmaceutics (2024) Vol. 22, Iss. 1, pp. 221-228
Closed Access
Xiaojiang Duan, Zhuochen Zhang, Hongchuang Xu, et al.
Molecular Pharmaceutics (2024) Vol. 22, Iss. 1, pp. 221-228
Closed Access
